SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics is conducting a public offering of 19.3 million…

SAB Biotherapeutics, Inc. · 8-K filed Mar 19, 2026 at 06:02 ET

At the news

BEARISHIMPACT 6/10

8-K filed Mar 19, 2026 at 06:02 ET

SAB Biotherapeutics is conducting a public offering of 19.3 million shares of common stock and pre-funded warrants to purchase up to 2.8 million shares at $3.85 per share, with an option for underwriters to purchase up to an additional 3.3 million shares. The company expects to raise approximately $69.7 million in net proceeds (up to $81.7 million if the option is exercised), which will be used primarily to fund clinical development of its lead product candidate SAB-142 for type 1 diabetes.

  • Offering includes 19,324,677 shares of common stock and pre-funded warrants for 2,753,246 shares at $3.85 per share
  • Underwriters have a 30-day option to purchase up to 3,311,688 additional shares
  • Expected net proceeds of $69.7 million ($81.7 million if option exercised), after underwriting discounts and expenses
  • Proceeds will be used to fund development of SAB-142 through clinical trials, manufacturing, regulatory activities, and general corporate purposes

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access